Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/6/2018
SIETES contiene 92381 citas

 
 
 1 a 20 de 60 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, for the Clinical Research Collaboration Neurological Emergencies Treatment Trials Network and the POINT Investigators.. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018:16 de mayo. [Ref.ID 102611]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]
4.Tiene citas relacionadas Cita con resumen
Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]
5.Tiene citas relacionadas Cita con resumen
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]
6. Cita con resumen
Guillón A, Suárez C, Díez-Manglano J, Formiga F, Cepeda JM, Pose A, Camafort M, Castiella J, Rovira E, Mostaza JM. Características y tratamiento antitrombótico de los pacientes ancianos con fibrilación auricular no valvular hospitalizados en Medicina Interna. Registro NONAVASC. Med Clin (Barc) 2017;148:204-10. [Ref.ID 101448]
7. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
8. Cita con resumen
Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]
9.Enlace a cita original
Timmis A, Rapsomaniki E, Chung SC, Pujades-Rodríguez M, Moayyeri A, Stogiannis D, Shah AD, Pasea L, Denaxas S, Emmas C, Hemingway H. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations. BMJ 2016;353:i3163. [Ref.ID 100471]
10. Cita con resumen
Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, for the DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016;315:1735-49. [Ref.ID 100183]
11. Cita con resumen
Voelker R. No increased risk of death with clopidogrel. JAMA 2015;314:2497. [Ref.ID 99759]
12. Cita con resumen
Young K. Who might benefit from long-term DAPT? Risk score may help . Journal Watch 2015:1. [Ref.ID 99636]
13. Cita con resumen
Olsen A-MS, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Lamberts M. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ 2015;351:h5096. [Ref.ID 99631]
15. Cita con resumen
Giustino G, Baber U, Sartori S, Mehran M, Mastoris I, Kini AS, Sharma SK, Pocock SJ, Dangas GD. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.. Journal of The Americal College of Cardiology 2015;65:1298-310. [Ref.ID 99446]
16. Cita con resumen
Pandit A, Giri S, Hakim FA, Fortiun FD. Shorter (=6 months) versus longer (=12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials. Catheterization and Cardiovascular Interventions 2015;85:34-40. [Ref.ID 99445]
17.Enlace a cita original Cita con resumen
Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials?. Eur Heart J 2015:6 de agosto. [Ref.ID 99343]
18.Tiene citas relacionadas Cita con resumen
Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong M-K, Kim B-K, Jang Y, Kim H-S, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385:2371-82. [Ref.ID 99292]
19.Tiene citas relacionadas Cita con resumen
Curzen N. Prolonged antiplatelet therapy after drug-eluting stents. Lancet 2015;385:2332-3. [Ref.ID 99289]
20. Cita con resumen
Spencer FA, Prasad M, Vandvik PO, Chetan D, Zhou Q, Guyatt G. Longer versus shorter duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 2015;163:118-26. [Ref.ID 99119]
Seleccionar todas
 
 1 a 20 de 60 siguiente >>